Bhattacharya et al. studied low-dose treatments of AITC in human bladder carcinoma (IC50 = 2.7 μM) and rat bladder carcinoma (IC50 = 3.3 μM), resulting in G2/M phase arrest and inhibiting the proliferation of bladder carcinogenic cell lines through the downregulation of cyclin B1 activity. This evidence concerns the gene CCNB1 and urinary bladder carcinoma.